Clinical Trials
Real World Results May Not Mirror Clinical Study Outcomes in Multiple Myeloma
August 07, 2018A prospective TLN cohort study demonstrated that trial eligibility is a strong predictor of progression-free and overall survival among patients with multiple myeloma.
Propolis Mouthwash Treatment Effectively Eases Severe Oral Mucositis
July 30, 2018In this systematic review, investigators sought to determine the safety, effectiveness, and tolerability of propolis mouthwash in preventing severe oral mucositis in patients undergoing chemotherapy or radiotherapy.
Patient Fears of Placebo Use in Clinical Trials
July 10, 2018What should be explained to patients regarding placebo use in controlled trials?
Cancer in Children and Adolescents (Fact Sheet)
June 05, 2018This fact sheet reviews cancer in adolescents and children, including possible causes, treatment, and the general outlook for childhood cancers.
NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
May 22, 2018A clinic staffed with clinical research nurses provided needed care for patients in clinical trials who experienced adverse effects, and also ensured consistent documentation of treatment-related AEs, according to a presentation at the 2018 ONS Annual Congress.
Clinical Research Nursing Staff an Important Part of Oncology Clinical Trial Programs
May 21, 2018The importance of oncology clinical research nurses in the clinical trial process was explored in a study presented at the 2018 ONS Annual Congress.
Online Program Aims to Assist With Clinical Trial Enrollment for Hematologic Cancers
May 19, 2018A newly developed web site, described in a presentation at the 2018 ONS Annual Congress, aims to help nurses and patients explore clinical trial options for patients with hematologic cancers.
Individual Meaning-Centered Psychotherapy May Improve Distress in Advanced Cancer
May 16, 2018A randomized study evaluated the effectiveness of individual meaning-centered psychotherapy on psychological outcomes and spiritual well-being for patients with advanced cancer, compared with enhanced usual care or supportive psychotherapy.
Can a Smartphone App Track Patient Symptoms During Clinical Trials?
May 10, 2018Researchers explored the effectiveness of using a smartphone app to monitor adverse effects of patients with cancer undergoing treatment as part of a clinical trial.
Study Links High Travel Burden, Clinical Trial Participation
May 03, 2018Travel to appointments can be difficult for patients with cancer. In this study, researchers sought to determine the effect of travel burden on clinical trial participation by household income, race/ethnicity, and clinical trial phase.
Elderly Patients Are Underrepresented in Trials For Soft Tissue Sarcoma
April 18, 2018With median age of participants in clinical trials for soft-tissue sarcoma younger than most patients who develop the disease, these researchers sought to determine the prevalence of including persons older than 65 in clinical trials and the efficacy of first-line chemotherapy for STS in older patients.
Progression-Free Survival Extended With PANEX Protocol in R/R Multiple Myeloma
April 17, 2018This treatment-expansion study evaluated the tolerability and safety of the PANEX (panobinostat plus bortezomib with dexamethasone) protocol in heavily treated patients with R/R multiple myeloma.
Long-term Carfilzomib May Be Safe, Effective In Relapsed Multiple Myeloma
April 06, 2018In a post-hoc analysis of the ASPIRE trial results, in which carfilzomib was discontinued due to a lack of long-term safety data, researchers present the safety and efficacy findings of KRd vs Rd for relapsed multiple myeloma at 18 months from randomization.
Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC
January 22, 2018Safety and efficacy of atezolizumab with cobimetinib for heavily pretreated metastatic CRC was demonstrated in a phase 1b study that was presented at the 2018 Gastrointestinal Cancers Symposium.
Survival Outcomes in Relapsed Hepatocellular Carcinoma Improved With Cabozantinib
January 19, 2018Results of the double-blind phase 3 CELESTIAL study, presented at the 2018 Gastrointestinal Cancers Symposium, demonstrated efficacy of cabozantinib in patients with HCC who were previously treated with sorafenib.
Bridging the Gap in Genetic Cancer Research Data on Minority Populations
January 01, 2018Investigators sought to determine why so few biospecimens were available for research from minority populations of women with breast cancer.
Current Findings in Trial Evaluating Paclitaxel Substitution in Invasive Breast Cancer
December 08, 2017Researchers presented an update of findings in the GeparSepto trial, which seeks to determine whether improvements in pathologic complete response can be translated to a survival benefit, at SABCS 2017.
Novel Predictive Model More Effectively Identifies Risk for Lung Cancer
October 20, 2017PanCan study results demonstrate the effectiveness of a novel predictive model in identifying risk of lung cancer in patients who do not meet the screening criteria of other models, including those used in the NLST.
Long-Term Eltrombopag Increases Platelet Counts, Decreases Bleeding in ITP
October 19, 2017Previous studies determined the effectiveness of 6 months of therapy with eltrombopag in patients with ITP. In this analysis, researchers extended 4 clinical trials to assess efficacy and safety of eltrombopag therapy for more than 6 months in patients with ITP.
New Class of Clinical Trial Enhances Research on Cancer Care Delivery
October 17, 2017What is a CCDR clinical trial and how does it differ from clinical trials that test new drugs?
Nivolumab Provides Better Long-Term Efficacy Compared With Docetaxel in NSCLC
October 16, 2017Two phase 3 studies reveal the clinical benefit, safety profile, and overall survival of nivolumab and docetaxel for patients with squamous and nonsquamous NSCLC.
High Rates of Adverse Events Lead to Earlier Dropouts in Phase 1 Cancer Trials
October 10, 2017Phase 1 trials are used to determine the safety profiles of treatment regimens. In this retrospective review, investigators sought to understand the reasons participants in these studies drop out.
Carfilzomib Improves Overall Survival in Relapsed/Refractory Multiple Myeloma
August 25, 2017The first interim analysis of the ENDEAVOR trial reported superiority of carfilzomib in some outcomes; however, data on overall survival were not available. This second interim analysis reports on overall survival with carfilzomib for patients with relapsed/refractory multiple myeloma.
More Patients Enrolled in Cancer Trials Under ACA
July 26, 2017Insurer approval rates rose from 85 percent before Affordable Care Act to 95 percent after the health care bill was enacted.
Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
June 28, 2017An analysis of rates at certain milestones in clinical trials of treatments for mNSCLC suggests these rates reflect end point results for immunotherapies vs targeted and conventional therapies.
Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
June 28, 2017Results of a phase 2 clinical trial of savolitinib, a highly selective small molecule inhibitor of c-Met, found the agent was active and tolerable in patients with Met-driven advanced or metastatic papillary renal cell carcinoma (PRCC).
Clinical Trials May Benefit Oncology Patients
June 22, 2017Research on the effects of research demonstrated that oncology-related clinical trials provide measurable benefits in terms
Older Patients Under-Represented in Cancer Drug Clinical Trials
June 15, 2017Older adults are underrepresented in clinical trials of cancer drugs, according to study findings presented at the 2017 ASCO Annual Meeting.
Older Adults Under-Represented in Cancer Drug Clinical Trials
June 08, 2017Patients aged 80 years and older had a cancer incidence of 16% in 2013 yet made up only 4% of cancer drug clinical trial participants during 2005-2015.
Sign Up for Free e-newsletters
ONA Articles
- Is Radioimmunotherapy a Path Forward for Melanoma?
- FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma
- New PDL1 Inhibitors for Non-small Cell Lung Cancer: Focus on Pembrolizumab
- Intensive Chemotherapy May Not Be Effective in MDS or AML After MDS
- ASCO Endorses SIO Guideline for Integrative Therapies in Breast Cancer
- NCCIH HerbList App Launched to Provide Information on Herbal Products
- Metformin Use May Improve Survival Outcomes in Bladder Cancer
- Higher Vitamin D Levels Associated With Lower Breast Cancer Risk
- Nurse-Led Program Improves Health, Financial Outcomes in Outpatient Chemotherapy
- Seeking Reliable Information on Herbal Products
- Disparities Remain in Prevalence of Cancer Screening Tests
- Hope, Gratitude, and Spirituality: What They Mean to Cancer Patients
- FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma
- 8 Hours of Bedrest May Be Ideal After Intrathecal Chemotherapy in Hematologic Cancers
- Combined Digital Screening Best for Detecting Breast Cancers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Genitourinary Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Rare Cancers | Regimens | |
| Skin Cancer | Regimens | Drugs |